STF 31Eliminates undifferentiated hPSCs from culture; also NAMPT and GLUT1 inhibitor CAS# 724741-75-7 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 724741-75-7 | SDF | Download SDF |
PubChem ID | 984333 | Appearance | Powder |
Formula | C23H25N3O3S | M.Wt | 423.53 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | DMSO : ≥ 34 mg/mL (80.28 mM) *"≥" means soluble, but saturation unknown. | ||
Chemical Name | 4-[[(4-tert-butylphenyl)sulfonylamino]methyl]-N-pyridin-3-ylbenzamide | ||
SMILES | CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)NCC2=CC=C(C=C2)C(=O)NC3=CN=CC=C3 | ||
Standard InChIKey | NGQPRVWTFNBUHA-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C23H25N3O3S/c1-23(2,3)19-10-12-21(13-11-19)30(28,29)25-15-17-6-8-18(9-7-17)22(27)26-20-5-4-14-24-16-20/h4-14,16,25H,15H2,1-3H3,(H,26,27) | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Inhibitor of GLUT1; inhibits glucose uptake in renal cell carcinoma (RCC) 4 cells. Activity causes necrotic cell death in von Hippel-Lindau (VHL)-deficient RCC cells. Also NAMPT inhibitor. Eliminates human pluripotent stem cells from culture with limited toxicity towards differentiated cells. |
STF 31 Dilution Calculator
STF 31 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.3611 mL | 11.8055 mL | 23.6111 mL | 47.2222 mL | 59.0277 mL |
5 mM | 0.4722 mL | 2.3611 mL | 4.7222 mL | 9.4444 mL | 11.8055 mL |
10 mM | 0.2361 mL | 1.1806 mL | 2.3611 mL | 4.7222 mL | 5.9028 mL |
50 mM | 0.0472 mL | 0.2361 mL | 0.4722 mL | 0.9444 mL | 1.1806 mL |
100 mM | 0.0236 mL | 0.1181 mL | 0.2361 mL | 0.4722 mL | 0.5903 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
STF-31 is an inhibitor of glucose transporter 1 (GLUT1, IC50 = 1 μM). IC50 value: 1 μM Target: GLUT1 in vitro: STF 31 is a glucose uptake inhibitor in RCC (renal cell carcinoma) 4 cells. By limiting glucose uptake in cancer cells, the immense energy requirements for the cancer cell is not met and the cell does not have the resources to rapidly proliferate.STF-31, which selectively kills RCCs by specifically targeting glucose uptake through GLUT1 and exploiting the unique dependence of these cells on GLUT1 for survival. STF-31 decreases glycolysis by decreasing glucose transport and not by inhibiting a particular glycolytic step or enzyme.[1] in vivo: STF-31 selectively targets the von Hippel-Lindau (VHL)-deficient kidney cancer cells. STF-31 inhibits VHL-deficient cancer cells by inhibiting Glut1. Daily intraperitoneal injection of a soluble analogue of STF-31 effectively reduces the growth of tumors of VHL-deficient cancer cells grafted on nude mice. On the other hand, STF-31 appears to be an inhibitor with a narrow cell target spectrum.[2]
References:
[1]. Chan DA, et al. Targeting GLUT1 and the Warburg effect in renal cell carcinoma by chemical synthetic lethality. Sci Transl Med. 2011 Aug 3;3(94):94ra70.
[2]. Liu Y, et al. A small-molecule inhibitor of glucose transporter 1 downregulates glycolysis, induces cell-cycle arrest, andinhibits cancer cell growth in vitro and in vivo. Mol Cancer Ther. 2012 Aug;11(8):1672-1682.
- Psora 4
Catalog No.:BCC7927
CAS No.:724709-68-6
- Praeruptorin C
Catalog No.:BCN4991
CAS No.:72463-77-5
- 11-Hydroxytephrosin
Catalog No.:BCN4861
CAS No.:72458-85-6
- Aniracetam
Catalog No.:BCC4219
CAS No.:72432-10-1
- Miglitol
Catalog No.:BCC4921
CAS No.:72432-03-2
- Acifran
Catalog No.:BCC7170
CAS No.:72420-38-3
- Aflatoxin G2
Catalog No.:BCC9215
CAS No.:7241-98-7
- Meglumine Metrizoate
Catalog No.:BCC5631
CAS No.:7241-11-4
- 6-Methoxydihydrosanguinarine
Catalog No.:BCN7581
CAS No.:72401-54-8
- X-Gal
Catalog No.:BCC1211
CAS No.:7240-90-6
- Oxacillin sodium monohydrate
Catalog No.:BCC4816
CAS No.:7240-38-2
- Yuheinoside
Catalog No.:BCN4279
CAS No.:72396-01-1
- Pirarubicin
Catalog No.:BCC5092
CAS No.:72496-41-4
- Methyl vanillate glucoside
Catalog No.:BCN4033
CAS No.:72500-11-9
- Felodipine
Catalog No.:BCC4402
CAS No.:72509-76-3
- Lycobetaine
Catalog No.:BCN8313
CAS No.:72510-04-4
- Specioside
Catalog No.:BCN4280
CAS No.:72514-90-0
- Paeonolide
Catalog No.:BCN2805
CAS No.:72520-92-4
- XCT790
Catalog No.:BCC5121
CAS No.:725247-18-7
- Polygonal
Catalog No.:BCN4281
CAS No.:72537-20-3
- 6-chloro-9h-fluoren-2-amine
Catalog No.:BCC9231
CAS No.:7254-05-9
- GIP (1-39)
Catalog No.:BCC5890
CAS No.:725474-97-5
- Ceftazidime
Catalog No.:BCC5274
CAS No.:72558-82-8
- Rifabutin
Catalog No.:BCC4936
CAS No.:72559-06-9
NAMPT is the cellular target of STF-31-like small-molecule probes.[Pubmed:25058389]
ACS Chem Biol. 2014 Oct 17;9(10):2247-54.
The small-molecule probes STF-31 and its analogue compound 146 were discovered while searching for compounds that kill VHL-deficient renal cell carcinoma cell lines selectively and have been reported to act via direct inhibition of the glucose transporter GLUT1. We profiled the sensitivity of 679 cancer cell lines to STF-31 and found that the pattern of response is tightly correlated with sensitivity to three different inhibitors of nicotinamide phosphoribosyltransferase (NAMPT). We also performed whole-exome next-generation sequencing of compound 146-resistant HCT116 clones and identified a recurrent NAMPT-H191R mutation. Ectopic expression of NAMPT-H191R conferred resistance to both STF-31 and compound 146 in cell lines. We further demonstrated that both STF-31 and compound 146 inhibit the enzymatic activity of NAMPT in a biochemical assay in vitro. Together, our cancer-cell profiling and genomic approaches identify NAMPT inhibition as a critical mechanism by which STF-31-like compounds inhibit cancer cells.
Inhibition of an NAD(+) salvage pathway provides efficient and selective toxicity to human pluripotent stem cells.[Pubmed:25834119]
Stem Cells Transl Med. 2015 May;4(5):483-93.
The tumorigenic potential of human pluripotent stem cells (hPSCs) is a major limitation to the widespread use of hPSC derivatives in the clinic. Here, we demonstrate that the small molecule STF-31 is effective at eliminating undifferentiated hPSCs across a broad range of cell culture conditions with important advantages over previously described methods that target metabolic processes. Although STF-31 was originally described as an inhibitor of glucose transporter 1, these data support the reclassification of STF-31 as a specific NAD(+) salvage pathway inhibitor through the inhibition of nicotinamide phosphoribosyltransferase (NAMPT). These findings demonstrate the importance of an NAD(+) salvage pathway in hPSC biology and describe how inhibition of NAMPT can effectively eliminate hPSCs from culture. These results will advance and accelerate the development of safe, clinically relevant hPSC-derived cell-based therapies.
Targeting GLUT1 and the Warburg effect in renal cell carcinoma by chemical synthetic lethality.[Pubmed:21813754]
Sci Transl Med. 2011 Aug 3;3(94):94ra70.
Identifying new targeted therapies that kill tumor cells while sparing normal tissue is a major challenge of cancer research. Using a high-throughput chemical synthetic lethal screen, we sought to identify compounds that exploit the loss of the von Hippel-Lindau (VHL) tumor suppressor gene, which occurs in about 80% of renal cell carcinomas (RCCs). RCCs, like many other cancers, are dependent on aerobic glycolysis for ATP production, a phenomenon known as the Warburg effect. The dependence of RCCs on glycolysis is in part a result of induction of glucose transporter 1 (GLUT1). Here, we report the identification of a class of compounds, the 3-series, exemplified by STF-31, which selectively kills RCCs by specifically targeting glucose uptake through GLUT1 and exploiting the unique dependence of these cells on GLUT1 for survival. Treatment with these agents inhibits the growth of RCCs by binding GLUT1 directly and impeding glucose uptake in vivo without toxicity to normal tissue. Activity of STF-31 in these experimental renal tumors can be monitored by [(18)F]fluorodeoxyglucose uptake by micro-positron emission tomography imaging, and therefore, these agents may be readily tested clinically in human tumors. Our results show that the Warburg effect confers distinct characteristics on tumor cells that can be selectively targeted for therapy.